Harley-Davidson is synonymous with power, heritage, and the spirit of freedom on two wheels. With over a century of legendary ...

The farnesoid X receptor (FXR) is a bile acid nuclear receptor that plays a crucial role in regulating bile acid and sterol metabolism. Bile acids are natural ligands of FXR, which bind to the ...

“We are excited to deliver FXR314 and our FXR program to Lilly for Phase 2 and further development. Their world-class development excellence and dedication to delivering for patients will ...

Organovo (ONVO) Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314. Under this transaction, Organovo will receive an ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. Organovo’s stock ...

Eli Lilly (LLY) has agreed to acquire Organovo Holdings’ (ONVO) FXR program, including its main drug candidate FXR314, to expand its IBD (inflammatory bowel disease) treatment pipeline.

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ farnesoid X receptor (FXR) agonist programme, aimed at treating ...

Hanwha Aerospace has embarked on an upgrade project to enlarge the payload fairing of domestically produced space launch vehicles to enable commercial launches. Initially, it was intended to be ...

"We are excited to deliver FXR314 and our FXR program to Lilly for Phase 2 and further development. Their world-class development excellence and dedication to delivering for patients will provide an ...

SAN DIEGO - Organovo Holdings, Inc. (NASDAQ:ONVO), a biotech firm specializing in 3D human tissue models, has reached an agreement to sell its FXR program, including the lead asset FXR314 ...